Find information on thousands of medical conditions and prescription drugs.

Colistin

Colistin (polymyxin E) is a polymyxin antibiotic produced by certain strains of Bacillus polymyxa var. colistinus. Colistin is a mixture of cyclic polypeptides colistin A and B. Colistin is effective against Gram-negative bacilli, except Proteus. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Administration

Colistin is used as a sulphate or as sulphomethylated form, colistimethate. Colistin sulphate tablets are used to treat intestinal infections, or to suppress colon flora. Colistin sulphate is also used as topical creams, powders, and otic solutions. Colistimethate is used for parenteral administration, and also as an aerosol to treat pulmonary infections.

Mode of action

Colistin is polycationic and has both hydrophobic and lipophilic moieties. These interact with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal.

Pharmacokinetics

The absorption of colistin from the gastrointestinal tract is very poor. The main elimination route of colistin is through renal excretion.

Read more at Wikipedia.org


[List your site here Free!]


Multi-drug-resistant acinetobacter fasciitis in a patient with perforated esophagus
From CHEST, 10/1/05 by Namrata Patil

INTRODUCTION: Multi-drug resistant Acinetobacter (MDRA) is not normally considered a pathogen for postoperative necrotizing fasciitis.

Changing epidemiological factors may contribute to increased recognition of this pathogen in nosocomial infections.

CASE PRESENTATION: Following a routine colonoscopy, a 69year old male with hypertension and peripheral vascular disease presented to an outside hospital with pleuritic chest pain and shortness of breath following several episodes of nausea and vomiting. A Chest CT scan showed a left sided pleural effusion. A chest tube was placed, and the patient was transferred to a tertiary care hospital with a diagnosis of an esophageal perforation. Upon arrival, he was emergently taken to the OR. He underwent a bronchoscopy, left sided thoracotomy with primary repair of a distal esophageal perforation with intercostal muscle flap, and a pericardial window. Postoperatively, the patient was intubated, maintained on vasopressors, and given broadspectrum antibiotics. Within the next 16 hrs the patient developed severe sepsis, manifested by renal failure and worsening hemodynamics. He developed multisystem organ failure. His serum creatinine kinase (CK) levels increased to 3,924, (baseline 259). Over the next 10 days, the BUN gradually increased to 99 (baseline 21), and his creatinine increased to 4.9. CK levels progressively increased and peaked at 143,000 (Fig. 1). He developed right lower extremity compartment syndrome, requiring bedside fasciotomies and right above knee amputation. Following the amputation, he developed frank cellulitis of his right stump, buttock and flank. At this point, the family decided against any more aggressive treatment. The patient died on POD 11. The muscle biopsy showed multi-drug resistant Acinetobacter Calcoaceticus-Baumanii complex, with intermediate sensitivity to Amikacin, Imipenem, Colistin, and Tobramycin. The only other positive culture was a sputum culture growing the same organism on POD&

DISCUSSIONS: Necrotizing fasciitis (NF) is a rapidly progressive infection of the subcutaneous tissues that leads to destruction of fascia and fat, characterized by fascial necrosis with thrombosis of the subcutaneous blood vessels, leading to cutaneous gangrene. Type I NF is a polymicrobial process, often seen in the postoperative setting and associated with gas formation. Type II NF is usually clue to infection with group A beta-hemolytic streptococci and occasionally in conjunction with Staph Aureus. Other reported organisms implicated in the pathogenesis include pseudomonas, Clostridia, Streptococcus pneumoniae, serratia, aeromonas, and vibrio. Acinetobacter is a free-living gram-negative bacterium, commonly found in water and soil. It is an inhabitant of the human skin. Acinetobacter baumannii is resistant to 'all available antibacterials except sublactum1. It has been identified as a difficult to eradicate nosocomial pathogen with a potential to cause opportunistic infections, leading to fatal disease in intensive care units. In the world's literature, there are only three cases reporting soft tissue infections caused by multi-drug resistant Acinetobacter1. Acinetobacter baumanni has been found to be an increasingly important cause of nosocomial infections, particularly in ICUs during the period between 1963-2003. This species has intrinsic resistance to certain antimicrobial agents, has acquired resistance, and has been reported to cause blood stream infections in patients at military medical-facilities treating service members injured in Afganistan, Iraq, and Kuwait1. Since MDRA poses therapeutic difficulties, spread of infection could be very hazardous.

CONCLUSION: Acinetobacter is an opportunistic pathogen in patients with severe co-morbidities. Although uncommon as a skin pathogen, acinetobacter may become a menacing agent in patients with necrotizing fasciitis. Given the potential of this multi-drug resistant organism to cause deadly outbreaks, the appropriately compromised host in the infectious cauldron of an ICU provides the setting for the perfect storm.

REFERENCE:

(1) Scott PT et al, Acinetobacter baumanuii Infections Among Patients at Military Medical Facilities Treating Injured U.S. Service Members, 2002-2004 Journal of American Medical Association 2004 Dec; 292(24):2964-66

DISCLOSURE: Namrata Patil, None.

Namrata Patil MD * Selwyn O. Rogers, Jr MD Brigham and Women's Hospital, Boston, MA

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Colistin
Home Contact Resources Exchange Links ebay